We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




High Aldolase Levels Indicate Muscle or Liver Damage

By LabMedica International staff writers
Posted on 30 Oct 2009
Print article
A new aldolase assay is aimed at diagnosing patients who have muscle or liver damage.

Aldolase is an enzyme that helps convert glucose into energy and is found throughout the body but is primarily found in high levels in muscle tissue. Elevated levels in the bloodstream can indicate a patient that has muscle or liver damage.

When the muscles are diseased or damaged, such as in muscular dystrophy, the cells deteriorate and break open causing the contents of the cells, including aldolase, to spill into the bloodstream. Aldolase is also found in the liver and cardiac muscle of the heart. Damage or disease to these organs, such as chronic hepatitis or a heart attack, will also increase aldolase levels in the blood.

Measuring the amount of aldolase in the blood indicates the degree of muscle damage. The Randox (Crumlin, UK) aldolase test is for the quantitative determination in serum or plasma and can be run manually or on the Randox RX series or on other automatic and semi-automatic analyzers.

Randox develops, manufactures, and markets clinical diagnostic products worldwide. Core products include: biochip array technology; clinical chemistry analyzers and reagents; and quality controls; recombinant proteins and antibodies.

Related Links:

Randox


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Biological Indicator Vials
BI-O.K.

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.